title: [Effectiveness of Live Attenuated Influenza Vaccines and Trivalent Inactivated Influenza Vaccines against confirmed Influenza In Children and Adolescents in Saxony-Anhalt, 2012/13].
abstract: Since 2012, there are not only trivalent inactivated influenza vaccines (TIV) but also live attenuated influenza vaccines (LAIV) available for children aged 2-17 years in Germany. The Saxony-Anhalt State Office for Consumer Protection conducted a test-negative case-control-study. The aim of the study was to identify the effectiveness of LAIV and TIV against a confirmed influenza diagnosis in children and adolescents in Saxony-Anhalt in the season 2012/13. The children had nasal swabs taken, which were further diagnosed in a laboratory using the PCR method. 834 patients of 15 voluntarily participating paediatric surgeries in Saxony-Anhalt were analysed by multivariate logistic regression with STATA 12. Controlling for age group, gender and month of the disease's onset showed an effectiveness of all vaccines amongst the 2-17 years old (38% with 95% CI: 0.8-61%; p=0.046). A differentiation according to LAIV and TIV demonstrated a significant effectiveness for LAIV (84%) in children of all ages (95% CI: 45-95%, p=0.004). After stratification for age groups LAIV was proven efficient in children aged 2-6 years (90% with 95% CI: 20-99%, p=0.03), whilst it led to a non-significant result in children aged 7-17 years (74% with 95% CI: -32-95%, p=0.106). There was no significant effectiveness of TIV seen in any age group.The Saxony-Anhalt State Office for Consumer Protection endorses the use of LAIV in children in accordance with the STIKO recommendations, as long as no contraindication is evident.
authors.affiliation: Fachhochschule bfi Wien, Wien.
authors.forename: N
authors.initials: N
authors.lastname: Hermann
mesh_terms: D000293:Adolescent; D017677:Age Distribution; D002648:Child; D002675:Child, Preschool; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D008297:Male; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D017678:Sex Distribution; D016896:Treatment Outcome; D014613:Vaccines, Attenuated / Q000008:administration & dosage; D015164:Vaccines, Inactivated / Q000008:administration & dosage
chemical_list: D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated